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The hypocretins/orexins are comprised of two neuroexcitatory peptides that are
synthesized exclusively within a circumscribed region of the lateral hypothalamus. These
peptides project widely throughout the brain and interact with a variety of regions involved
in the regulation of arousal-related processes including those associated with motivated
behavior. The current review focuses on emerging evidence indicating that the hypocretins
influence reward and reinforcement processing via actions on the mesolimbic dopamine
system. We discuss contemporary perspectives of hypocretin regulation of mesolimbic
dopamine signaling in both drug free and drug states, as well as hypocretin regulation of
behavioral responses to drugs of abuse, particularly as it relates to cocaine.
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BRIEF INTRODUCTION TO THE HYPOCRETIN/OREXIN
SYSTEM
The hypocretin/orexin system consists of two neuroexcitatory
peptides (hypocretin-1 and hypocretin-2) that are synthesized
within neurons restricted to the lateral hypothalamus and adja-
cent regions. These neurons project to a vast number of brain
regions and interact with two known G-protein-coupled recep-
tors, the hypocretin 1 and hypocretin 2 receptors (de Lecea et al.,
1998; Sakurai et al., 1998; Zhu et al., 2003). Both hypocretin
receptors are expressed widely throughout the brain although
their expression levels vary based on location (Trivedi et al., 1998;
Bourgin et al., 2000; Greco and Shiromani, 2001; Hervieu et al.,
2001; Marcus et al., 2001; Backberg et al., 2002; Cluderay et al.,
2002; Suzuki et al., 2002). The widespread distribution patterns
of fibers and receptors positions the hypocretin system to inter-
act with a variety of neural structures known to be involved
in the regulation of arousal-related processes. It is posited that
the hypocretins modulate a number of cognitive, affective, and
homeostatic processes associated with arousal via these interac-
tions (Peyron et al., 1998; Piper et al., 2000; España et al., 2001;
Adamantidis et al., 2007).
Over the past decade, a series of studies has expanded
our understanding of hypocretin involvement in arousal-
related processes and their influence on motivated behavior,
reward/reinforcement, and the neural mechanisms underlying
these actions. These studies have demonstrated that enhancement
of hypocretin signaling promotes neurochemical and behavioral
responses to drugs of abuse, while manipulations that reduce
hypocretin signaling disrupt these responses. The present review
will focus on hypocretin regulation of baseline and cocaine-
induced changes in dopamine signaling as well as motivated
behaviors reliant on dopamine neurotransmission.
HYPOCRETIN REGULATES BASELINE LEVELS OF
DOPAMINE SIGNALING
Accumulating evidence indicates that the hypocretin system
regulates dopamine function via direct actions on hypocretin
receptors within the ventral tegmental area (VTA) where a large
populationofdopamineneurons resides. Thefirst evidence for this
came from anatomical studies showing a significant hypocretin
innervation of the VTAwhere both hypocretin 1 and hypocretin 2
receptors are found on dopamine neurons (Marcus et al., 2001;
Fadel and Deutch, 2002; Baldo et al., 2003; Narita et al., 2006).
Consistentwith these observations, hypocretins increase tonic and
burst firing of dopamine neurons in the VTA, further signifying
that hypocretins regulate dopamine function (Korotkova et al.,
2003). Conversely, blockade of hypocretin 1 receptors reduces
dopamine cell firing (Moorman and Aston-Jones, 2010).
Although there is substantial evidence for direct excita-
tory actions of hypocretins throughout the brain, including
on dopamine neurons of the VTA (Ivanov and Aston-Jones,
2000; Korotkova et al., 2003, 2006; Moorman and Aston-Jones,
2010), several observations suggest that hypocretins also facil-
itate glutamatergic excitation of VTA dopamine neurons. For
instance, Borgland and colleagues have shown elegantly that
both hypocretin-1 and -2 augment glutamatergic excitability
of dopamine neurons (Borgland et al., 2006, 2008), likely via
hypocretin-induced increases in synaptic NMDA receptors within
the VTA (Borgland et al., 2006). Importantly, blockade of
hypocretin 1 receptors using SB-334867 reduces the hypocretin-
1-mediated enhancement of NMDA receptor currents of VTA
dopamine neurons (Borgland et al., 2006). Other evidence for
hypocretin facilitation of glutamate-mediated excitation of VTA
dopamine neurons comes from experiments where VTA neuronal
firing was elicited by stimulation of the medial prefrontal cortex
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which provides significant glutamatergic innervation to the VTA.
When delivered directly into the VTA, hypocretin-1 potentiated
dopamine cell firing elicited by cortex stimulation, indicating that
synaptic connections between cortical glutamatergic neurons and
dopamine cell bodies are responsive to hypocretins (Moorman
and Aston-Jones, 2010). When taken together, these observations
provide strong evidence for hypocretin regulation of dopaminer-
gic firing, in part, by facilitating glutamatergic signaling within
the VTA.
The consequences of hypocretin-mediated alterations in
dopamine neuronal activity are evident in a series of studies
investigating the effects of hypocretins on synaptic dopamine
transmission under baseline conditions. Initial studies using
microdialysis have demonstrated inconsistent effects of hypocre-
tin on tonic dopamine levels. For instance, one study using
hypocretin-1 infusions into the VTA showed marked increases
in dopamine levels in the NAc, although it is unclear to what
extent the NAc core or shell was targeted (Narita et al., 2006).
In another study, hypocretin-1 infusions into the VTA failed to
show increases in dopamine within the NAc core, but did show
dopamine elevations in the prefrontal cortex and the NAc shell
(Vittoz and Berridge, 2006; Vittoz et al., 2008). Consistent with
this latter observation, in recent studies we have also shown a lack
of hypocretin-1 effect on baseline dopamine signaling in the NAc
core (España et al., 2011).
Despite the inconsistencies observed with experiments test-
ing the effects of enhanced hypocretin neurotransmission on
dopamine signaling, it remained possible that some degree of
hypocretin tone was necessary for normal dopamine function.
To examine this, we again used microdialysis to test the effects
of hypocretin 1 receptor blockade on dopamine signaling in the
NAc core (España et al., 2010). These studies used the selec-
tive hypocretin 1 receptor antagonists, SB-334867 which has
50-fold selectivity for the hypocretin 1 receptor over the hypocre-
tin 2 receptor (Smart et al., 2001). Additionally, this antagonist
has been reported to have no appreciable selectivity for over
50 other G-protein coupled receptors and ion channels (Smart
et al., 2001). On testing days, rats were pretreated with i.p. vehi-
cle or 30mg/kg SB-334867 and dopamine levels were sampled
for thirty minutes before the animal received a second manip-
ulation (see below for description of cocaine studies). As might
be predicted from the lack of effects observed with previous
hypocretin-1 studies, i.p. injections of SB-334867 had little effect
on dopamine levels under baseline conditions, although a small
trend for reduced dopamine was observed. These observations are
in agreement with another recent microdialysis study in which
subcutaneous SB-334867 injections did not alter baseline levels
of dopamine in the NAc shell (Quarta et al., 2010). Interestingly,
however, we repeated these studies with the exception that rats
were treated with SB-334867 (10 nmol) directly into the VTA.
Using this approach, blockade of hypocretin 1 receptors signif-
icantly reduced dopamine levels in the NAc core (España et al.,
2010). Although it is unclear why i.p. injections of SB-334867
failed to reduce dopamine signaling, the fact that intra-VTA
SB-334867 infusions significantly reduced baseline dopamine
suggests that hypocretin neurotransmission within this region is
important for normal dopamine signaling.
Although microdialysis is a useful technique, it suffers from
relatively low temporal resolution and solely provides infor-
mation on tonic changes in dopamine signaling that typically
occur over extended periods of time (typically 10–20min sam-
pling). In contrast, the high temporal resolution afforded by
fast scan cyclic voltammetry allows for rapid sampling of phasic
changes in both dopamine release and uptake. Using voltam-
metry in anesthetized rats we further explored the possibility
that hypocretin regulates dopamine signaling (España et al.,
2010, 2011). Rats were implanted with a recording electrode in
the NAc core and an infusion cannula affixed to a stimulating
electrode in the VTA. Under these conditions, electrical stim-
ulation of the VTA elicits consistent action-potential-mediated
dopamine efflux which can be used to measure changes in the
amplitude of dopamine release (peak height in µM) as well as
the rate of dopamine uptake (Vmax) via the dopamine trans-
porter. In initial studies, rats were pretreated with vehicle or
hypocretin-1 (0.5 nmol) directly into the VTA and dopamine sig-
naling was recorded for 20min prior to additional manipulations
(see cocaine results below). In contrast to what was observed with
the microdialysis studies, hypocretin-1 significantly increased
evoked-dopamine release within 5min of administration with-
out affecting dopamine uptake rate (Figure 1A; España et al.,
2011).
Consistent with these findings, disruption of hypocretin neu-
rotransmission produces the opposite effects. Thus, in another
set of studies, rats received an infusion of vehicle or SB-334867
(10 nmol) directly into the VTA and dopamine responses were
monitored for 40mins (España et al., 2010). Relative to vehicle-
treated rats, SB-334867 produced a significant reduction in
stimulated dopamine release, further indicating that hypocre-
tin signaling regulates dopamine neurotransmission (Figure 1B).
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FIGURE 1 | Hypocretin manipulations influence evoked dopamine
release under baseline conditions. Shown are the mean ± SEM of
peak heights of stimulated dopamine (DA) release for rats that received
(A) vehicle (n = 6) or 1 nmol hypocretin-1 (n = 6) into the VTA, or (B) vehicle
(n = 8) or 10 nmol SB-334867 (n = 6) into the VTA. Compared to vehicle,
hypocretin-1 increased, while SB-334867 reduced the peak height of
stimulated dopamine release in the NAc core. ∗ P < 0.05 relative to vehicle.
Modified from España et al. (2010, 2011).
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Additionally, in a final set of experiments, we used in vitro
voltammetry in brain slices from wild type (WT) and hypocre-
tin knockout (KO) mice to examine whether a complete loss of
hypocretin signaling would produce deficits in dopamine signal-
ing. Hypocretin KO and WT mice were sacrificed and recording
and stimulating electrodes were positioned within the NAc core
to allow for measurement of locally-evoked dopamine release
(España et al., 2010). Table 1 shows that under baseline condi-
tions, hypocretin KO mice displayed reductions in both evoked
dopamine release and dopamine uptake rate, again indicating that
hypocretin neurotransmission is necessary to maintain normal
levels of dopamine signaling.
SUMMARY
Despite somewhat conflicting observations, the neurochemical
studies described above indicate that the hypocretin system influ-
ences some aspects of dopamine signaling under normal, baseline
conditions. Microdialysis studies suggest that hypocretin signal-
ing regulates dopamine levels in the prefrontal cortex and possibly
the NAc shell, while voltammetry studies show that hypocretin
signaling is necessary to maintain normal levels of dopamine
release within the NAc core. Together, these observations offer
further support for the hypothesis that the hypocretin system
participates in the regulation of dopamine signaling and that
hypocretin actions on dopamine systems could influence behav-
iors known to be regulated by dopamine.
HYPOCRETIN REGULATES DRUG-INDUCED CHANGES
IN DOPAMINE SIGNALING
In addition to regulating dopamine signaling under baseline con-
ditions, hypocretins also exert a profound influence on dopamine
responses to drugs of abuse. For example, in brain slices con-
taining the VTA, hypocretin-1 enhanced cocaine-induced poten-
tiation of glutamatergic currents (AMAPA/NMDAR ratio) in
dopamine neurons in animals that had received non-contingent
cocaine injections. Importantly, these effects were blocked with
SB-334867 (Borgland et al., 2006). Moreover, a recent study
demonstrates that a history of cocaine self-administration pref-
erentially enhances hypocretin-1 potentiation of NMDA receptor
Table 1 | Hypocretin KO mice show disrupted dopamine signaling
under baseline conditions and in response to cocaine.
Group Baseline Baseline Uptake Inhibition
[DAp] Vmax (apparent affinity Km)
WT 1.69 ± 2.5 µM 3.5 ± 0.4 µM/s 22.5 ± 3.5 µM
KO 1.04 ± 2.2 µM∗ 2.1 ± 0.3 µM/s∗∗ 10.9 ± 1.2 µM∗∗
Shown are mean ± SEM for baseline levels of dopamine release [DAp] and max-
imal uptake rate (Vmax), as well as cocaine-induced dopamine uptake inhibition
(apparent affinity Km) for WT and hypocretin KO mouse slices containing the NAc
core. Under baseline conditions, hypocretin KO mice show reduced dopamine
release and reduced dopamine uptake rates relative to WT mice. Following
superfusion of 30 uM cocaine, cocaine-induced dopamine uptake inhibition was
significantly lower in hypocretin KO mice. ∗P < 0.05; ∗∗P < 0.01. Modified from
España et al. (2010).
plasticity in VTA neurons (Borgland et al., 2009). The hypocretin-
mediated augmentation in VTA gultamatergic transmission
appears to occur selectively with highly salient reinforcers such
as cocaine and high fat food pellets as this potentiation did not
occur following aversive stimuli such as foot shock (Borgland
et al., 2009).
In a series of neurochemical studies we examined the effects
of hypocretin manipulations on dopamine responses to cocaine.
In initial experiments, rats were implanted for microdialysis sam-
pling in the NAc core and dopamine levels were measured in
response to treatment with hypocretin agents and cocaine. Rats
were pretreated with vehicle or hypocretin-1 (0.5 nmol) directly
into the VTA 20min prior to receiving a single 10mg/kg injec-
tion of cocaine. In rats treated with vehicle, injections of cocaine
produced expected increases in extracellular dopamine levels.
In contrast, hypocretin-1 significantly augmented the effects of
cocaine to nearly double of what was observed with vehicle
(Figure 2A; España et al., 2011). The opposite effect was observed
when hypocretin neurotransmission was compromised. Thus,
rats pretreated with i.p. or intra-VTA SB-334867 showed signifi-
cantly lower levels of dopamine in response to cocaine (Figure 2B;
España et al., 2010). These data are consistent with another set
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FIGURE 2 | Hypocretin manipulations influence cocaine-induced
elevations in extracellular dopamine within the NAc core. (A) Shown
are the mean ± SEM of extracellular levels of dopamine (DA) within the
NAc core following intra-VTA infusion of vehicle (n = 6) or 0.5 nmol
hypocretin-1 (HCRT-1; n = 6). (B) Shown are the mean ± SEM of
extracellular levels of dopamine (DA) within the NAc core following i.p.
injection of vehicle (n = 6) or 30mg/kg SB-334867 (n = 6). ∗P < 0.05,
∗∗P < 0.01 relative to vehicle. Modified from España et al. (2010, 2011).
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of studies showing that i.p. SB-334867 reduces the effects of
amphetamine on dopamine levels in the NAc shell (Quarta et al.,
2010) and that hypocretin KO mice show reduced extracellular
dopamine responses to morphine and cocaine (Narita et al., 2006;
España and Jones, 2010).
A similar set of results was also obtained in studies using
voltammetry in anesthetized rats (España et al., 2010, 2011). As
described above, rats were implanted with a recording electrode
in the NAc core, an infusion cannula/stimulating electrode in
the ipsilateral VTA, and an i.v. jugular catheter for delivery of
cocaine. On testing days, rats were pretreated with vehicle or
hypocretin-1 (0.5 nmol) into the VTA 20min prior to receiv-
ing 1.5mg/kg i.v. cocaine. As shown in Figures 3A,B, within 30 s
of cocaine delivery, hypocretin-1 pretreated animals showed sig-
nificantly greater evoked dopamine release than animals treated
with vehicle (España et al., 2011). Moreover, hypocretin-1 also
augmented cocaine-induced uptake inhibition suggesting that
dopamine neurons were more sensitive to the effects of cocaine.
As expected, voltammetry experiments using SB-334867 showed
the opposite effects (España et al., 2010). Rats received an infu-
sion of vehicle or SB-334867 (10 nmol) directly into the VTA
40minutes prior to i.v. delivery of cocaine (1.5mg/kg). When
compared to vehicle-treated animals, SB-334867 significantly
reduced the effects of cocaine on both dopamine peak height
and dopamine uptake inhibition, signifying that cocaine was no
longer as effective at inhibiting dopamine uptake (Figures 3C,D).
Consistent with these observations, in vitro voltammetry in brain
slices from WT and hypocretin KO mice demonstrate that in
addition to baseline disruptions in dopamine signaling, a loss
of hypocretin also reduces the effects of cocaine on evoked
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FIGURE 3 | Hypocretin signaling influences cocaine-induced changes in
evoked-dopamine release and uptake in the NAc core. (A,B) Shown are
representative concentration-time plots and cyclic voltammograms (insets) of
dopamine responses from rats that received pretreatment infusions of
vehicle or 0.5 nmol hypocretin-1 into the VTA. (C,D) Shown are representative
concentration-time plots and cyclic voltammograms (insets) of dopamine
responses from rats that received pretreatment infusions of vehicle or
10 nmol SB-334867 into the VTA. Stim represents the time of electrical
stimulation (1 s, 60Hz pulse). (Insets in A–D) Cyclic voltammograms depict
two current peaks, one at 600mV (positive deflection) for dopamine oxidation
and one at –200mV (negative deflection) for reduction of
dopamine-o-quinone. The position of the peaks identifies the substance
oxidized as dopamine. Compared to their respective vehicle groups,
hypocretin-1 augments, while SB334867 reduces, the effects of cocaine on
both evoked dopamine release and dopamine uptake inhibition. Modified
from España et al. (2010, 2011).
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dopamine release and dopamine uptake inhibition (España et al.,
2010).
POTENTIAL MECHANISMS UNDERLYING HYPOCRETIN
MODULATION OF DOPAMINE SIGNALING
Although the mechanisms involved in hypocretin regulation of
dopamine neurotransmission are not yet understood, there is
evidence that hypocretins may influence baseline dopamine sig-
naling and dopamine responses to drugs of abuse by altering the
activity state of dopamine neurons in the VTA. As mentioned
above, hypocretins promote glutamatergic enhancement of exci-
tatory synaptic transmission in dopamine neurons of the VTA
(Borgland et al., 2006, 2009), and in our voltammetry studies we
show that hypocretin agents within the VTA alter dopamine sig-
naling under baseline conditions and following cocaine (España
et al., 2010, 2011). These effects are consistent with previous
work indicating that hypocretin manipulations alter dopamine
cell firing (Ivanov and Aston-Jones, 2000; Korotkova et al., 2003,
2006; Moorman and Aston-Jones, 2010). We posit that by alter-
ing the activity state of dopamine neurons, hypocretins not
only affect dopamine transmission directly, but may also exert
effects that serve to alter the sensitivity of dopamine systems
to drug treatments. In terms of cocaine, observed increases in
dopamine levels within terminal regions are known to be associ-
ated with blockade of the dopamine transporter (Ritz et al., 1987).
Nevertheless, recent observations indicate that in addition to
blocking dopamine uptake, cocaine stimulates glutamate release
in the VTA (Wise et al., 2008) and increases the incidence and/or
magnitude of dopamine release events in the NAc shell (Aragona
et al., 2008). These two latter observations provide additional
mechanisms for increased dopamine signaling that may not be
directly reliant on dopamine transporter function. Based on this
evidence, it is possible that by altering baseline dopamine activity
via changes in dopamine neuron firing or sensitivity to gluta-
mate, hypocretin manipulations could induce dopamine neurons
to display a differential sensitivity to cocaine and possibly other
drugs of abuse.
Another possibility is that the hypocretin system influences
dopamine signaling by altering the functional state of dopamine
terminals. The dopamine transporter can be modulated via a
number of second messenger signaling cascades that result in
phosphorylation and glycosylation, both of which can alter the
stability of the dopamine transporter in the membrane (Li et al.,
2004; Johnson et al., 2005; Mortensen et al., 2008). Given that
baseline uptake rates are dependent on functional dopamine
transporters, modifications that alter dopamine transporter lev-
els at the cell surface result in changes to baseline dopamine
uptake rates, an effect that can alter psychostimulant potency.
In addition, dopamine transporter trafficking to the membrane
can occur rapidly, in as little as 10 s, therefore it is not sur-
prising that acute treatment with hypocretin agents can alter
the potency of psychostimulants such as cocaine (Furman et al.,
2009). One explanation for how hypocretin manipulations in
the VTA can alter dopamine signaling in dopamine terminal
regions is through hypocretin’s ability to alter dopamine release.
By altering dopamine levels at the synapse, hypocretin manipu-
lations can influence activation of dopamine D2 autoreceptors,
which have been shown to directly modulate dopamine trans-
porter activity. For example, drugs that act upon D2 receptors
influence dopamine uptake rates via disruptions in dopamine
transporter function, with D2 agonists increasing, and D2 antag-
onists decreasing dopamine uptake rates (Meiergerd et al., 1993).
A similar finding is observed with D2 KO animals, which dis-
play decreased dopamine transporter function (Dickinson et al.,
1999). These changes in dopamine uptake following D2 manipu-
lations are likely associated with trafficking of dopamine trans-
porters, as it has been shown that the presence of D2 recep-
tors facilitates intracellular dopamine transporters to move to
the cell surface (Lee et al., 2007). In this manner it is possi-
ble that, by regulating dopamine neuronal firing, hypocretins
impact D2 autoreceptor receptor activity, not only affecting
the activity state of dopamine neurons, but also D2 related
dopamine transporter function and related changes in dopamine
uptake.
In either case, it is likely that under baseline conditions, nor-
mal levels of hypocretin tone serves to facilitate dopamine neu-
ronal responsivity to afferent signals (e.g., glutamate) such that
dopamine neurons will fire and release dopamine at levels appro-
priate for typical responses to drugs of abuse. Under these circum-
stances cocaine can exert its typical effects and elevate dopamine
levels in target regions. However, when hypocretin neurotrans-
mission is enhanced or compromised, dopamine neuronal activ-
ity and release are affected. In the case of reduced hypocretin
signaling, (e.g., via SB-334867 treatment), dopamine neuronal
activity state would be compromised and thus dopamine release
and sensitivity to glutamate would similarly be reduced leading to
dysregulation in dopamine transporter function and alterations
in the ability for cocaine to exert its effects.
SUMMARY
The neurochemical studies described above provide compelling
evidence for the hypothesis that hypocretin neurotransmission
influences dopamine signaling in the NAc core, particularly in
response to cocaine. Moreover, given that many of the described
experiments used infusions of agents directly into the VTA, these
studies indicate that the actions of hypocretin on dopamine
release and uptake involve signaling within the VTA and pos-
sibly enhancement of glutamatergic signaling within dopamine
neurons in this region.
HYPOCRETIN INVOLVEMENT IN REWARD AND
REINFORCEMENT PROCESSES
The mesolimbic dopamine system, including the projection from
the VTA to the NAc, is hypothesized to play an integral role
in the reinforcing properties of various stimuli including food,
sex, and drugs of abuse such as cocaine (Roberts et al., 1977;
Woolverton and Johnson, 1992; Robinson and Berridge, 1993;
Wise, 1996; Koob and Le Moal, 1997; Volkow and Wise, 2005).
Given the observations that hypocretin neurons project to and
modulate dopamine function, and that hypocretin manipulations
results in altered dopamine responses to drugs of abuse, it is likely
that the hypocretin system also participates in the regulation of
reward and reinforcement related behaviors. Over the past sev-
eral years, multiple reports have focused on the extent to which
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the hypocretin system influences behavioral responses to cocaine
and other drugs of abuse, in part, via actions on the mesolimbic
dopamine system.
HYPOCRETIN NEURONS ARE ACTIVATED BY DRUGS OF ABUSE
A number of studies have demonstrated that hypocretin neu-
rons are activated by psychostimulants and other drugs of abuse.
For example, acute injections of methamphetamine or nicotine
(Ko et al., 2003; Pasumarthi et al., 2006) increase Fos immunore-
activity in hypocretin neurons to three times the levels observed
under control conditions. In addition, chronic nicotine also
increases hypocretin peptide and hypocretin receptor mRNA lev-
els (Kane et al., 2000). By comparison, cessation of chronic drug
delivery and subsequent withdrawal can also elicit activation of
hypocretin neurons. Naloxone-induced withdrawal from chronic
morphine increases Fos in hypocretin neurons and increases lev-
els of hypocretin peptide mRNA in the NAc shell (Georgescu
et al., 2003; Zhou et al., 2006; Sharf et al., 2008). It appears
that hypocretin 1 receptors are involved in these actions given
that SB-334867 attenuates symptoms of morphine withdrawal
and associated changes in Fos in the NAc shell (Sharf et al.,
2008). Finally, it has also been shown that hypocretin neurons
show increased Fos following presentation of a drug associated
cue. In one study using a model of drug relapse, rats that were
exposed to an environment previously associated with ethanol
reward showed significantly higher Fos levels in hypocretin neu-
rons than animals exposed to a neutral environment (Dayas et al.,
2008).
CONDITIONED PLACE PREFERENCE
The previous Fos observations demonstrate that hypocretin neu-
rons are responsive to administration of various drugs of abuse.
Whether the increased activity of hypocretin neurons is sim-
ply associated with a generalized drug effect on arousal or
with more direct actions on reward mechanisms is not fully
known. Nevertheless, some studies suggest that general effects
of these drugs cannot solely explain the effects of cocaine and
morphine on hypocretin neuronal activity. For example, Harris
and colleagues demonstrate that hypocretin neurons are pref-
erentially activated in animals that develop CPP for morphine
or cocaine and not in those that fail to acquire CPP (Harris
et al., 2005; Harris and Aston-Jones, 2006). Specifically, rats
that acquired CPP had 3-fold greater numbers of Fos-positive
hypocretin neurons than naïve animals or animals that were
treated with these drugs but did not acquire CPP. In another
set of studies, it was also shown that the degree of Fos activa-
tion was proportional to the magnitude of CPP obtained with
chemical activation of hypocretin neurons, again suggesting that
hypocretin activity is responsive to the rewarding aspects of these
drugs.
The importance of hypocretin signaling in reward-related pro-
cesses is also evident in CPP experiments using SB-334867. For
example, systemic SB-334867 has been shown to prevent CPP for
amphetamine (Hutcheson et al., 2011) and for morphine (Harris
et al., 2005). Furthermore, single infusions of SB-334967 into the
VTA block morphine CPP (Narita et al., 2006; Sharf et al., 2010),
as do unilateral lesions of the lateral hypothalamus combined
with contralateral SB-33467 infusions into the VTA (Harris et al.,
2007). Interestingly, while systemic administration of SB-334867
is capable of blocking CPP for morphine (Harris et al., 2005;
Sharf et al., 2010) it is unclear as to its effects on cocaine-induced
CPP. For example, Sartor and Aston-Jones demonstrate that sys-
temic administration of SB-332867 blocks cocaine-induced CPP
in rats (Sartor and Aston-Jones, 2012), while others show a lack
of SB-332867 effects on CPP following treatment in mice (Sharf
et al., 2010).
A complete disruption of hypocretin signaling also produces
deficits in behavioral responsivity to drugs of abuse. Hypocretin
KO mice display decreased morphine dependence, reduced loco-
motor and dopamine responses to morphine, and they fail to
exhibit morphine CPP (Georgescu et al., 2003; Narita et al., 2006;
Sharf et al., 2010). In preliminary studies we demonstrated that
hypocretin KO mice are also less sensitive to the rewarding prop-
erties of cocaine (España and Jones, 2010). In those studies,
WT mice showed typical levels of CPP for cocaine. In contrast,
however, hypocretin KO mice showed a non-significant trend
toward conditioned place aversion. When taken together, these
CPP results indicate that hypocretin signaling is critical for the
regulation of the rewarding properties of cocaine and other drugs
of abuse.
LOCOMOTOR SENSITIZATION
Locomotor sensitization is characterized by an increase in
locomotor responses to a drug challenge after repeated adminis-
tration of the drug. Although the mechanisms underlying loco-
motor sensitization remain poorly understood, this paradigm
provides a useful metric for investigating the neural bases of
long-term behavioral plasticity which are thought to be medi-
ated, in part, by alterations in dopamine systems (Kalivas et al.,
1992). Several observations suggest that the hypocretin sys-
tem is involved in the development of locomotor sensitization
for a variety of drugs including cocaine and amphetamine.
McPherson and colleagues showed that amphetamine sensiti-
zation results in increased activation of hypocretin neurons,
an effect that was not observed with acute amphetamine
treatment (McPherson et al., 2007). Locomotor sensitization
by amphetamine requires activation NMDA receptors in the
VTA, which as described above, is influenced by the hypocre-
tin system (Vezina and Queen, 2000; Borgland et al., 2006).
Consequently, it is not surprising that locomotor sensitization
with amphetamine can be disrupted with SB-334867 injec-
tions (Quarta et al., 2010). Similarly, locomotor sensitization
to cocaine can be blocked by i.p. or intra-VTA SB-334867
administration when it is delivered prior to exposure to cocaine
(Borgland et al., 2006). Like that posited for amphetamine, it
is believed that disruption in cocaine locomotor sensitization
is associated with the ability of hypocretins to recruit NMDA
receptors to the membrane within the VTA (Borgland et al.,
2006). In contrast to that seen with cocaine and amphetamine,
however, locomotor sensitization to morphine is unaffected by
hypocretin 1 receptor blockade, suggesting the likelihood that
opiates do not share the same pathway as psychostimulants
for the development of locomotor sensitization (Sharf et al.,
2010).
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SELF-ADMINISTRATION
Although multiple behavioral approaches have been used
to examine drug-seeking and drug-taking in rodents, i.v.
self-administration is frequently considered to be the pre-
ferred method for modeling drug abuse. The flexibility of
self-administration techniques allows investigators to vary the
schedules of reinforcement so as to parse the effects of drug treat-
ments on the acquisition and maintenance phases of drug intake,
on the propensity to relapse, and to model specific aspects of
cocaine intake, including drug consumption, diurnal variations
in cocaine intake, and the motivation to work for cocaine. The
following section will discuss recent observations demonstrating
the importance of the hypocretin system in self-administration of
cocaine and other drugs of abuse.
Maintenance
The extent to which hypocretins regulate the reinforcing actions
of drugs has been studied across varying schedules of rein-
forcement. In initial studies, rats were implanted with a jugular
catheter and then trained to self-administer cocaine on a fixed
ratio 1 (FR1) schedule of reinforcement in which single lever
presses resulted in cocaine delivery (Aston-Jones et al., 2009;
España et al., 2010). With little restriction to cocaine access, rats
are easily able to titrate blood levels of cocaine by spacing injec-
tions out over a session, and consequently, responding on an
FR1 schedule provides information about an animal’s preferred
level of cocaine consumption (Norman and Tsibulsky, 2006).
After reaching stable levels of cocaine self-administration, rats
were treated with vehicle or 30mg/kg SB-334867 and the number
of cocaine injections taken per hour was assessed. Under these
conditions, treatment with SB-334867 has no effect on cocaine
consumption. A similar lack of effect on FR1 responding was
observed when rats were infused with hypocretin-1 directly into
the lateral ventricles (Boutrel et al., 2005; España et al., 2011).
These initial observations suggested that active cocaine self-
administration was not influenced by the hypocretin system.
Nevertheless, several subsequent reports that employed vary-
ing schedules of reinforcement demonstrated significant effects
of hypocretin manipulations on self-administration of drugs of
abuse. For example, blockade of hypocretin 1 receptors decreased
responding for nicotine on an FR5 schedule (Hollander et al.,
2008; Corrigall, 2009) and ethanol on an FR3 schedule (Lawrence
et al., 2006; Richards et al., 2008). The same sensitivity to hypocre-
tin agents is observed when using a 24 h access, discrete trials
(DT) schedule in which animals have the opportunity to obtain
cocaine only three times per hour. By restricting cocaine access
to every 20min, rats are unable to maximize their blood lev-
els of cocaine and a characteristic pattern of intake emerges
in which rats take cocaine almost exclusively during the dark-
phase (Roberts et al., 2002; España et al., 2010). Although, the
effort requirement is low in a DT paradigm (one lever response
results in cocaine delivery), the interaction between dose and
availability makes this schedule particularly sensitive to pharma-
cological and physiological influences which under less restricted
access conditions are not observed. As shown in Figure 4, i.c.v.
infusions of hypocretin-1 (0.5 nmol) promoted cocaine intake
within 20min of delivery thereby effectively extending cocaine
self-administration into the light-phase (España et al., 2011). By
comparison, i.p. injections of SB-334867 reduced cocaine intake,
particularly in rats treated with the highest dose of SB-334867
(España et al., 2010).
The progressive ratio (PR) schedule of reinforcement is
designed to assess an animal’s motivation to work for a reinforcer.
In the initial stages of a PR session, single cocaine injections are
obtained with relatively low effort (few lever responses) and thus
like an FR1 schedule, animals can readily attain preferred blood
levels of cocaine. However, as the PR session continues, lever
response requirements increase for subsequent cocaine injec-
tions and thus rats must exert greater effort to obtain cocaine.
The point at which animals discontinue to work for the rein-
forcer is termed the “breakpoint” and is a measure of the effort
that an animal is willing to expend to obtain drug (Richardson
and Roberts, 1996). Using the PR schedule, we recently showed
that bilateral, but not unilateral intra-VTA infusions of the
hypocretin-1 increased the motivation to take cocaine (España
et al., 2011). As shown in Figure 5, animals treated with bilat-
eral hypocretin-1 engaged in significantly more lever pressing
and reached higher breakpoints than animals treated with vehicle
(Figure 5). Consistent with these findings, disruption of hypocre-
tin signaling produces the opposite effect. Thus, both i.p. and
bilateral intra-VTA injections of SB-334867 decreased break-
points and lever response number (Figure 6). These effects are
in line with recent reports showing that i.p. SB-334867 reduces
PR responding for cocaine, nicotine, or heroin (Hollander et al.,
2008; Borgland et al., 2009; Smith and Aston-Jones, 2012). The
effects of SB-332867 on PR responding do not generalize to
all reinforcers. Although this antagonist reduces breakpoints for
cocaine and high-fat food pellets, it has little effect on breakpoints
for a regular food reinforcer (Borgland et al., 2009). This is par-
ticularly relevant when considering the possible use of hypocretin
drugs for the treatment of addiction, as this data suggests that a
propensity for an individual to work for drug could be reduced
without interfering with the motivation to obtain natural and
possibly less salient reinforcer, such as food.
The threshold schedule of reinforcement has been used to
examine consumption and motivation within a single session
(España et al., 2010). During the early portions of a threshold
session, single lever responses result in delivery of high doses
of cocaine and thus rats can easily attain preferred levels of
cocaine. Under these conditions, SB-334867 has no effect on
cocaine intake, similar to what is observed with an FR1 schedule.
Nevertheless, as the dose of cocaine is lowered across the session,
rats must elicit increasingly higher numbers of lever responses to
maintain blood levels of cocaine. At this higher price of cocaine,
injections of SB-334867 reduce responding earlier in the session,
and thus less cocaine intake is observed (Figure 7).
Reinstatement
Reinstatement of drug seeking behavior is a useful method to
assess the propensity to relapse by measuring a return of operant
drug seeking following a period of forced abstinence. Drug seek-
ing can be reinstated by various methods including presentation
of drug or context cues, stress, or administration of various phar-
macological agents (Crombag et al., 2002; Boutrel et al., 2005;
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FIGURE 4 | Hypocretin signaling regulates cocaine self-administration
on a DT schedule of reinforcement. (A) Shown are the mean ± SEM
number of cocaine injections taken over the 6 h period following infusion of
vehicle (n = 7) or 0.5 nmol hypocretin-1 (HCRT-1; n = 7). (B) Shown is a
response pattern from an individual rat that received vehicle (white arrow) or
0.5 nmol hypocretin-1 (black arrow) into the lateral ventricle. (C) Shown are
the mean ± SEM number of cocaine injections taken over the 6 h period
following i.p. injections of vehicle (n = 8) or SB-334867 (7.5, 15, and 30mg/kg;
n = 8). (D) Shown is a response pattern from an individual rat that received
an i.p. vehicle (white arrow) or 30mg/kg SB-334867 injection (black arrow).
Horizontal rasters represent 24 h periods. Vertical tick marks represent trials
in which a 1.5mg/kg cocaine injection was taken. Compared to their
respective vehicle groups, hypocretin-1 promotes, while SB334867 reduces,
cocaine intake. Note that for SB-334867 experiments, rats were treated at
11:00 am when rats are typically awake, whereas for hypocretin-1
experiments, rats were treated at 3:00 pm a time when rats typically
discontinue taking cocaine. * P < 0.05, ** P < 0.01 relative to vehicle.
Modified from España et al. (2010, 2011).
Smith et al., 2010). Several research groups have examined the
effects of hypocretin agents on reinstatement of drug seeking
behavior. For instance, i.c.v. infusions of hypocretin-1 are suf-
ficient to reinstate cocaine and nicotine seeking (Boutrel et al.,
2005; Plaza-Zabala et al., 2010), while peripheral treatment with
SB-334967 reduces cue-induced reinstatement of ethanol and
cocaine seeking (Lawrence et al., 2006; Smith et al., 2009). This
reduction in cocaine seeking could be due, in part, to hypocretin
actions in the VTA, as intra-VTA infusions of SB-332867 result in
a reduction in cue-induced reinstatement of cocaine (James et al.,
2011;Mahler et al., 2012). Further,Mahler and colleagues demon-
strate that these effects are due to the ability of hypocretin to
facilitate AMPA responses to glutamate inputs related to the cues
associated with prior self-administration (Mahler et al., 2012).
Although they demonstrate that this is a potential mechanism
for cue-induced reinstatement, the same drugs failed to affect
cocaine-primed reinstatement, indicating that this is a mecha-
nism specific to the drug paired cues. Furthermore, SB-334867
also attenuates stress-induced reinstatement of cocaine-seeking.
In those studies, peripheral SB-334867 reduced reinstatement
of cocaine seeking following both foot shock and yohimbine-
induced stress (Boutrel et al., 2005; Richards et al., 2008).
SUMMARY
The self-administration studies described above have shown a
series of consistent findings indicating a prominent role for the
hypocretin system in the regulation of reinforcement processes.
In general, manipulations that reduce hypocretin signaling result
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FIGURE 5 | Hypocretin infusions into the VTA increase the motivation
to take cocaine on a PR schedule of reinforcement. (A) Shown are the
mean ± SEM number of cocaine breakpoints and lever responses following
unilateral or bilateral intra-VTA infusions of vehicle (uni, n = 5; bilat, n = 6)
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responding. ∗ P < 0.05 relative to vehicle. Modified from España et al.
(2011).
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FIGURE 6 | SB-334867 infusions into the VTA decrease the motivation
to take cocaine on a PR schedule of reinforcement. (A) Shown are the
mean ± SEM number of cocaine breakpoints and lever responses following
unilateral or bilateral intra-VTA infusions of vehicle (uni, n = 5; bilat, n = 6)
or 10 nmol SB-334867 (uni, n = 5; bilat, n = 6). (B) Shown are event records
from an individual rat that received an i.p. injection of vehicle or 30mg/kg
SB-334867. Cocaine injections taken are indicated by diagonal tick marks.
Relative to vehicle, SB-334867 decreases the motivation to take cocaine as
evidenced by decreased breakpoints and lever responding. ∗∗ P < 0.01
relative to vehicle. Modified from España et al. (2010).
in reduced motivation to work for drugs, specifically under con-
ditions where drug availability is limited or where a substantial
amount of effort must be expended for an animal to obtain
drug. In contrast, under conditions that do not require much
effort, and animals can maximize blood levels of drug, hypocre-
tin disruptions do not affect drug intake. The opposite findings
are observed when hypocretin signaling is enhanced. This only
holds true for highly salient reinforcers, as SB-334867 infusions
do not affect the effort that an animal is willing to exert to obtain
normal food reward. Thus, infusions of hypocretin-1 increase
the motivation to work for drugs under conditions that require
effortful responding. Together these observations indicate that the
hypocretin system regulates behavioral responses associated with
cocaine and other highly salient reinforcers.
HYPOCRETIN INVOLVEMENT IN AROUSAL
Many observations indicate that the hypocretin system reg-
ulates arousal-related processes, including locomotor activity
and sleep-wake behavior (Hagan et al., 1999; Bourgin et al.,
2000; Piper et al., 2000; España et al., 2001). Consequently,
it has been posited that hypocretin manipulations influence
self-administration via gross deficits in arousal or motor func-
tion rather than through actions on reinforcement mechanisms.
Despite this possibility, several observations argue against this
hypothesis. First, previous studies indicate that while treat-
ment with hypocretin peptides promotes a high arousal state,
blockade of hypocretin 1 receptors does not elicit sleep and
does not alter responding for natural rewards including water
and food (Lawrence et al., 2006; Deng et al., 2007; Rasmussen
et al., 2007; Hollander et al., 2008; Borgland et al., 2009;
Dugovic et al., 2009). In particular, our work indicates that, in
food restricted rats, sucrose self-administration is unaffected by
SB-334867 at doses that significantly reduce cocaine intake and
sucrose self-administration in sated animals (España et al., 2010).
Furthermore, FR1 studies from multiple research groups demon-
strate that blockade of hypocretin-1 receptors does not affect the
rate of cocaine responding, indicating that rats maintain nor-
mal motoric responses on levers (Aston-Jones et al., 2009; España
et al., 2010). Lastly, our recent studies demonstrate that locomo-
tor activity in response to cocaine remains unchanged following
SB-334867 administration. In those studies, rats were treated
with varying doses of SB-334867 (7.5, 15, and 30mg/kg) and
30min later were introduced into a novel, open-field, locomotor
chamber. Locomotor activity (distance traveled in cm) was mea-
sured using automated computer-based calculation of infrared
photobeam crossings. After 40min of baseline locomotor test-
ing, rats were treated with a single i.p. injection of 10mg/kg
cocaine, and locomotor activity wasmeasured for another 90min.
Data were analyzed as area under the curve collapsed across time
as independent One-Way ANOVAs for the pre-cocaine acclima-
tion period and for the post-cocaine testing period using SPSS
20 (International Business Machines Corp, Armonk, NY). As
shown in Figure 8, during the first 40min of testing a modest
decrease in baseline locomotor activity was observed following
SB-334867 treatment [F(3, 41) = 6.82, p < 0.001]. Nevertheless,
a Tukey’s post-hoc test indicated that this effect was only sig-
nificant at 30mg/kg SB-334867 (p < 0.001). More importantly,
however, when rats were challenged with an i.p. dose of 10mg/kg
cocaine, there were no significant differences in locomotor activ-
ity across doses of SB-334867 [F(3, 41) = 2.54, p < 0.07]. In fact,
rats treated with 30mg/kg showed the highest levels of activity
when compared to all other groups, suggesting that when cocaine
is on board, rats treated with SB-334867 do not display overall
disruptions to arousal or deficits in locomotor activity.
These observations indicate that while hypocretin manipula-
tions may affect some aspects of arousal, they do not produce
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FIGURE 8 | SB-334867 does not reduce cocaine-induced locomotor
activity. Shown are the mean ± SEM of locomotor activity expressed as
distance traveled (cm) for animals treated with i.p. vehicle (n = 26) or
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following cocaine injections, the 30mg/kg SB-334867 group showed the
highest amount of locomotor activity. ∗P < 0.05, relative to vehicle.
sedation or locomotor deficits that would explain reductions
in behavioral responses to drugs of abuse. Indeed, blockade of
hypocretin 1 receptors does not reduce locomotor responses to
cocaine, has no effect on lever responding under an FR1 or
sucrose-reinforced PR schedule in highly-motivated rats. When
considered together, these data suggest that the pharmacological
effects of SB-334867 on motivated responding for cocaine cannot
be solely attributable to sedation or disruptions to motor activity.
CONCLUSIONS
In less than a decade, nearly a hundred articles have focused on
the involvement of the hypocretin system in regulating natural
and drug reward. Studies using a variety of electrophysiologi-
cal, neurochemical, molecular, and behavioral approaches have
shown that the hypocretin system is important for normal neu-
rotransmitter and behavioral responses to drugs of abuse. At a
gross level, it is evident that enhancement of hypocretin signaling
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enhances behavioral responses to the rewarding properties of
drugs, promotes the motivation for animals to work for drugs of
abuse, and increases the propensity for drug seeking and drug tak-
ing. By comparison, disruptions in hypocretin signaling reduce
drug reward, decrease the motivation to work for drugs, and
reduce drug intake and drug seeking.
The effects of hypocretin on behavioral responses to drugs of
abuse are likely to be associated with alterations in dopamine
neuronal activity in the VTA. Many observations indicate that
under normal conditions hypocretins influence dopamine cell fir-
ing and dopamine release across regions in the brain that are
known to participate in reward and reinforcement processes.
Furthermore, it is clear that manipulations to hypocretin neu-
rotransmission also affect dopamine responses to drugs of abuse
with enhancement of dopamine release observed with increased
hypocretin signaling and reduced dopamine release seen when
hypocretin neurotransmission is disrupted. Whether hypocretin
regulation of dopamine signaling is a principal participant in
the alterations observed with behavioral responses to drugs of
abuse is unclear. Nevertheless, given the importance of dopamine
systems in regulating reward and reinforcement-related behav-
iors, it appears that the hypocretin system may be a viable tar-
get for pharmacotherapy development to treat drug dependence
and relapse without the abuse potential, or intolerability, asso-
ciated with many of the current treatments for drug addiction.
Furthermore, given the evidence that hypocretins also modulate
the motivation to work for palatable foods when rats are hun-
gry, but not when they are sated, suggests that the hypocretins
may also serve as targets for the treatment of addiction to natu-
ral reinforcers, in general, and not only for addiction to drugs of
abuse.
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